The CEO said Sellas is pursuing a “security force” immunotherapy strategy that trains immune cells to recognize cancer even as tumors evolve.

Acute myeloid leukemia, often called AML, is one of the most aggressive forms of blood cancer. It develops in the bone marrow, the soft tissue inside bones where blood cells are made. In healthy ...

An investigational approach to diagnosis of prostate cancer uses sound waves to extract "bubbles of information" from cells. ...

Investors are monitoring the Miami Cancer Institute Immunotherapies Summit, where Sellas' scientific advisor, Guenther Koehne ...

Investigators at CHOP and UPenn found that lower cell counts could still be associated with poor outcomes if the cells were poorly differentiated.

KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions –– Market feedback emphasizes differentiated ...

CD25 expression has long been recognized as an adverse prognostic marker in acute leukemias including acute myeloid leukemia ...

Acute myeloid leukemia, or AML, is a rare and aggressive cancer that can affect people of all ages. Kiran Vanaja, an ...

Soheil Meshinchi, MD, PhD, a world leader in developing novel approaches to treating acute myeloid leukemia (AML), has been ...

Pillar Biosciences today announced the launch of the oncoReveal ® Rapid AML Panel, a focused research-use-only (RUO) DNA next-generation sequencing (NGS) panel designed to help laboratories generate ...

Structural nanomedicine — what helped give us the COVID vaccine — may now be the key to a potent blood cancer treatment that’s had remarkable early results.

A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving acute myeloid leukemia (AML), an aggressive blood cancer affecting the bone ...